Citations

Clear

4203 citation(s) found for "Yu, Chen".

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
Goss, Paul E. , Shepherd, Lois E. , Chapman, J. W. , Chen, Bingshu E. , Kubo, Michiaki , Furukawa, Yoichi , Momozawa, Yukihide , Stearns, Vered , Barman, Poulami , Weinshilboum, Richard M. , Kalari, Krishna R. , Wang, Liewei , Xie, Fang , Ingle, James N. , Xie, Fang , Ellis, Matthew J. , Chapman, Judith‐Anne W. , Pritchard, Kathleen I. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M. , Stearns, Vered , Chen, Bingshu E , Kalari, Krishna R

Mayo Clinic

Cancer Research | October 11, 2016 | Volume: 76 | Issue: 23 | Pages: 7012-7023

10.1158/0008-5472.can-16-1371 | PMID 27758888 Get It

Abstract Genetic risks in breast cancer remain only partly understood. Here, we report the results of a genome-wide association study of germline DNA from 4,658 women, including 252 women experiencing a breast cancer recurrence, who were entered on the MA.27 adjuvant trial comparing the aromatase inhibitors (AI) anastrozole and exemestane. Single-nucleotide polymorphisms (SNP) of top significance were identified in the gene encoding MIR2052HG, a long noncoding RNA of unknown function. Heterozygous or homozygous individuals for variant alleles exhibited a ∼40% or ∼63% decrease, respectively, in the hazard of breast cancer recurrence relative to homozygous wild-type individuals. Functional genomic studies in lymphoblastoid cell lines and ERα-positive breast cancer cell lines showed that expression from MIR2052HG and the ESR1 gene encoding estrogen receptor-α (ERα) was induced by estrogen and AI in a SNP-dependent manner. Variant SNP genotypes exhibited increased ERα binding to estrogen response elements, relative to wild-type genotypes, a pattern that was reversed by AI treatment. Further, variant SNPs were associated with lower expression of MIR2052HG and ERα. RNAi-mediated silencing of MIR2052HG in breast cancer cell lines decreased ERα expression, cell proliferation, and anchorage-independent colony formation. Mechanistic investigations revealed that MIR2052HG sustained ERα levels both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated, proteasome-dependent degradation of ERα. Taken together, our results define MIR2052HS as a functionally polymorphic gene that affects risks of breast cancer recurrence in women treated with AI. More broadly, our results offer a pharmacogenomic basis to understand differences in the response of breast cancer patients to AI therapy. Cancer Res; 76(23); 7012–23. ©2016 AACR.
A Case of Simultaneous Benign Metastasizing Leiomyomas and Disseminated Peritoneal Leiomyomatosis Following Endoscopic Power Morcellation for Uterine Disease
Park, Beau Y., Leslie, Kevin O., Vaszar, Laszlo T. , Cornella, Jeffrey L. , Chen, Longwen

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | September 30, 2016 | Volume: 23 | Issue: 1 | Pages: e1-e3

10.1097/spv.0000000000000342 | PMID 27748666 Get It

Abstract Extrauterine spread of leiomyomas is rare and most commonly occurs in the lungs. We present a case of simultaneous metastatic leiomyomatosis to the lungs and peritoneal cavity following laparoscopic myomectomy with power morcellation. The patient presented to our institution for further management where she underwent a robotically assisted hysterectomy with bilateral salpingo-oophorectomy. Leiomyomatous implants measuring up to 2.4 cm were resected from bowel mesentery and bladder peritoneum. Subsequent serial computed tomography imaging confirmed stable pulmonary nodules without new intraperitoneal lesions. Increasing number of cases involving extrauterine spread of leiomyomas has been reported with the introduction of power morcellation. The exact pathogenesis is unknown but is likely multifactorial. We emphasize that although the incidence of spread of benign disease is low, it is important to recognize this phenomenon as we will likely continue to encounter similar cases in the coming years.
Considering sex as a biological variable in preclinical research
Miller, Leah, Marks, Cheryl L., Hurn, Patricia D., Woodruff, Teresa K. , Sohrabji, Farida , Schiebinger, Londa , Wetherington, Cora Lee, Makris, Susan L. , Arnold, Arthur P. , Einstein, Gillian , Miller, Virginia M. , Sandberg, Kathryn , Maier, Susan, Cornelison, Terri L., Becker, Jill B. , Chen, Wei‐Jung , McCarthy, Margaret M. , Clayton, Janine A. , Schiebinger, Londa

Mayo Clinic

The FASEB Journal | September 28, 2016 | Volume: 31 | Issue: 1 | Pages: 29-34

10.1096/fj.201600781r | PMID 27682203 Get It

In June 2015, the National Institutes of Health (NIH) released a Guide notice (NOT‐OD‐15–102) that highlighted the expectation of the NIH that the possible role of sex as a biologic variable be factored into research design, analyses, and reporting of vertebrate animal and human studies. Anticipating these guidelines, the NIH Office of Research on Women's Health, in October 2014, convened key stakeholders to discuss methods and techniques for integrating sex as a biologic variable in preclinical research. The workshop focused on practical methods, experimental design, and approaches to statistical analyses in the use of both male and female animals, cells, and tissues in preclinical research. Workshop participants also considered gender as a modifier of biology. This article builds on the workshop and is meant as a guide to preclinical investigators as they consider methods and techniques for inclusion of both sexes in preclinical research and is not intended to prescribe exhaustive/specific approaches for compliance with the new NIH policy.—Miller, L. R., Marks, C., Becker, J.B., Hurn, P.D., Chen, W.‐J., Woodruff, T., McCarthy, M.M., Sohrabji, F., Schiebinger, L., Wetherington, C.L., Makris, S., Arnold, A. P., Einstein, G., Miller, V. M., Sandberg, K., Maier, S., Cornelison, T. L., Clayton, J. A. Considering sex as a biological variable in preclinical research. FASEB J. 31, 29–34 (2017) www.fasebj.org
Shifts in the Fecal Microbiota Associated with Adenomatous Polyps
Hale, Vanessa L. , Johnson, Stephen , Harrington, Sean C., Yab, Tracy C. , Smyrk, Thomas C. , Nelson, Heidi , Boardman, Lisa A., Druliner, Brooke R., Levin, Theodore R. , Rex, Douglas K. , Ahnen, Dennis J. , Lance, Peter , Ahlquist, David A. , Chia, Nicholas , Chen, Jun , Boardman, Lisa A., Druliner, Brooke R. , Chia, Nicholas

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 26, 2016 | Volume: 26 | Issue: 1 | Pages: 85-94

10.1158/1055-9965.epi-16-0337 | PMID 27672054 Get It

Abstract Background: Adenomatous polyps are the most common precursor to colorectal cancer, the second leading cause of cancer-related death in the United States. We sought to learn more about early events of carcinogenesis by investigating shifts in the gut microbiota of patients with adenomas. Methods: We analyzed 16S rRNA gene sequences from the fecal microbiota of patients with adenomas (n = 233) and without (n = 547). Results: Multiple taxa were significantly more abundant in patients with adenomas, including Bilophila, Desulfovibrio, proinflammatory bacteria in the genus Mogibacterium, and multiple Bacteroidetes species. Patients without adenomas had greater abundances of Veillonella, Firmicutes (Order Clostridia), and Actinobacteria (family Bifidobacteriales). Our findings were consistent with previously reported shifts in the gut microbiota of colorectal cancer patients. Importantly, the altered adenoma profile is predicted to increase primary and secondary bile acid production, as well as starch, sucrose, lipid, and phenylpropanoid metabolism. Conclusions: These data hint that increased sugar, protein, and lipid metabolism along with increased bile acid production could promote a colonic environment that supports the growth of bile-tolerant microbes such as Bilophilia and Desulfovibrio. In turn, these microbes may produce genotoxic or inflammatory metabolites such as H2S and secondary bile acids, which could play a role in catalyzing adenoma development and eventually colorectal cancer. Impact: This study suggests a plausible biological mechanism to explain the links between shifts in the microbiota and colorectal cancer. This represents a first step toward resolving the complex interactions that shape the adenoma–carcinoma sequence of colorectal cancer and may facilitate personalized therapeutics focused on the microbiota. Cancer Epidemiol Biomarkers Prev; 26(1); 85–94. ©2016 AACR.
The Impact of Transferred Vascularized Toe Joint Length on Motion Arc of Reconstructed Finger Proximal Interphalangeal Joint
Hsu, Chung‐Chen , Loh, Charles Yuen Yung , Moran, Steven L. , Lin, Yu‐Te

Mayo Clinic

HAND | September 26, 2016 | Volume: 11 | Issue: 1_suppl | Pages: 18S-18S

10.1177/1558944716660555ii Get It

Objective: Vascularized toe joint transfer for finger proximal interphalangeal joint (PIPJ) reconstruction is a well-described technique in the literature. However, the reconstructed PIPJ is known to have issues with suboptimal range of motion and extension lag. One of the reasons for this problem is the length of the intercalated bony segment. There is a lack of evidence and consensus regarding the optimal length of the intercalated segment. This study hence was performed to determine the impact of the intercalated segment length on the subsequent passive arc of motion (AOM) and extension lag of the reconstructed PIPJ. Materials and Methods: We harvested the intercalated joint graft (the toe PIPJ along with its associated extensor tendons) from the lesser toes and transferred it to the finger of cadavers. A predetermined constant PIPJ defect size of 2 cm was created on the finger. By insetting 3 different lengths of the intercalated segment to the finger PIPJ, we investigated the effect of shortened (1.5 cm), exact (2.0 cm), or lengthened (2.5 cm) intercalated segment lengths on the AOM and extension lag of the reconstructed PIPJ. Results: The average AOM of finger PIPJ was 81.0° ± 19.1° and that of the toe PIPJ was 53.6° ± 16.1°. In the group with longer intercalated segment, the average AOM was 29.9° ± 10.5° with an extension lag of 32° ± 11.7°. In the group with equal intercalated segment length, the average AOM was 49.1° ± 11.5° with an extension lag of 15.4° ± 10.6°. In the group with shorter intercalated segment, the average AOM was 70.9° ± 12.6° with an extension lag of 8.4° ± 8.9°. Conclusions: From our study, shortening the intercalated segment may provide the most reduction in the extension lag of the reconstructed PIPJ. Future studies could involve further refinement of the amount of length to be shortened. This would probably lie between 0 to 5 mm.
Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality
Nicolas, Clara T., Nyberg, Scott L. , Watt, Kymberly D. , Chen, Harvey S., Hathcock, Matthew , Kremers, Walter K. , Watt, Kymberly, Hathcock, Matthew A, Heimbach, Julie K. , Kremers, Walter K

Mayo Clinic

Liver Transplantation | September 22, 2016 | Volume: 23 | Issue: 1 | Pages: 11-18

10.1002/lt.24641 | PMID 27658200 Get It

Share 35 was implemented in 2013 to direct livers to the most urgent candidates by prioritizing Model for End‐Stage Liver Disease (MELD) ≥ 35 patients. We aim to evaluate this policy's impact on costs and mortality. Our study includes 834 wait‐listed patients and 338 patients who received deceased donor, solitary liver transplants at Mayo Clinic between January 2010 and December 2014. Of these patients, 101 (30%) underwent transplantation after Share 35. After Share 35, 29 (28.7%) MELD ≥ 35 patients received transplants, as opposed to 46 (19.4%) in the pre–Share 35 era (P = 0.06). No significant difference in 90‐day wait‐list mortality (P = 0.29) nor 365‐day posttransplant mortality (P = 0.68) was found between patients transplanted before or after Share 35. Mean costs were $3,049 (P = 0.30), $5226 (P = 0.18), and $10,826 (P = 0.03) lower post‐Share 35 for the 30‐, 90‐, and 365‐day pretransplant periods, and mean costs were $5010 (P = 0.41) and $5859 (P = 0.57) higher, and $9145 (P = 0.54) lower post‐Share 35 for the 30‐, 90‐, and 365‐day posttransplant periods. In conclusion, the added cost of transplanting more MELD ≥ 35 patients may be offset by pretransplant care cost reduction. Despite shifting organs to critically ill patients, Share 35 has not impacted mortality significantly. Liver Transplantation 23:11–18 2017 AASLD.
Incorporating Functional Annotations for Fine-Mapping Causal Variants in a Bayesian Framework Using Summary Statistics
Chen, Wenan , McDonnell, Shannon K. , Thibodeau, Stephen N. , Tillmans, Lori S. , Schaid, Daniel J. , McDonnell, Shannon K

Mayo Clinic

Genetics | September 21, 2016 | Volume: 204 | Issue: 3 | Pages: 933-958

10.1534/genetics.116.188953 | PMID 27655946 Get It

Abstract Functional annotations have been shown to improve both the discovery power and fine-mapping accuracy in genome-wide association studies. However, the optimal strategy to incorporate the large number of existing annotations is still not clear. In this study, we propose a Bayesian framework to incorporate functional annotations in a systematic manner. We compute the maximum a posteriori solution and use cross validation to find the optimal penalty parameters. By extending our previous fine-mapping method CAVIARBF into this framework, we require only summary statistics as input. We also derived an exact calculation of Bayes factors using summary statistics for quantitative traits, which is necessary when a large proportion of trait variance is explained by the variants of interest, such as in fine mapping expression quantitative trait loci (eQTL). We compared the proposed method with PAINTOR using different strategies to combine annotations. Simulation results show that the proposed method achieves the best accuracy in identifying causal variants among the different strategies and methods compared. We also find that for annotations with moderate effects from a large annotation pool, screening annotations individually and then combining the top annotations can produce overly optimistic results. We applied these methods on two real data sets: a meta-analysis result of lipid traits and a cis-eQTL study of normal prostate tissues. For the eQTL data, incorporating annotations significantly increased the number of potential causal variants with high probabilities.
Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts
Nicolas, Clara T., Chen, Harvey S., Mao, Shennen A. , Higuita, Manuela Lopera , Wang, Yujia , Nyberg, Scott L. , Hickey, Raymond D, Lopera Higuita, Manuela, Hickey, Raymond , Mao, Shennen A

Mayo Clinic

Stem Cells | September 19, 2016 | Volume: 35 | Issue: 1 | Pages: 42-50

10.1002/stem.2500 | PMID 27641427 Get It

Abstract Donor organ shortage is the main limitation to liver transplantation as a treatment for end-stage liver disease and acute liver failure. Liver regenerative medicine may in the future offer an alternative form of therapy for these diseases, be it through cell transplantation, bioartificial liver (BAL) devices, or bioengineered whole organ liver transplantation. All three strategies have shown promising results in the past decade. However, before they are incorporated into widespread clinical practice, the ideal cell type for each treatment modality must be found, and an adequate amount of metabolically active, functional cells must be able to be produced. Research is ongoing in hepatocyte expansion techniques, use of xenogeneic cells, and differentiation of stem cell-derived hepatocyte-like cells (HLCs). HLCs are a few steps away from clinical application, but may be very useful in individualized drug development and toxicity testing, as well as disease modeling. Finally, safety concerns including tumorigenicity and xenozoonosis must also be addressed before cell transplantation, BAL devices, and bioengineered livers occupy their clinical niche. This review aims to highlight the most recent advances and provide an updated view of the current state of affairs in the field of liver regenerative medicine.
Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma
Kutsenko, Alina , Ladenheim, Maya R., Kim, Nathan G. , Nguyen, Pauline, Chen, Vincent , Jayasekera, Channa R. , Yang, Ju Dong , Kumari, Radhika, Roberts, Lewis R. , Nguyen, Mindie H. , Yang, Ju Dong , Roberts, Lewis R , Chen, V L

Mayo Clinic

Journal of Clinical Gastroenterology | September 16, 2016 | Volume: 51 | Issue: 4 | Pages: 384-390

10.1097/mcg.0000000000000689 | PMID 27636408 Get It

Background: We used metabolic risk factors to estimate the prevalence and clinical significance of nonalcoholic fatty liver disease in Asian Americans with hepatocellular carcinoma (HCC). Methods: This is a retrospective cohort study of 824 consecutive Asian HCC patients at Stanford University Medical Center from 1998 to 2015. Patients were subdivided as: Chinese, other East Asian (Japanese and Korean), South East Asian (Vietnamese, Thai, and Laotian), Maritime South East Asian (MSEA: Malaysian, Indonesian, Filipino, and Singaporean), and South West Asian (Indian, Pakistani, and Middle Eastern). Metabolic risk factors studied were body mass index, hypertension, type II diabetes, and hyperlipidemia. Results: Most patients were male (76%) with mean age 63 years. Metabolic risk factors were highly prevalent on presentation and increased over time (P<0.001), as did the prevalence of cryptogenic HCC (P<0.004). Compared with other Asian subgroups, MSEAs had the highest body mass index (26.3) and higher rates of type II diabetes (44% vs. 23% to 35%, P=0.004), hypertension (59% vs. 38% to 55%, P=0.04), and cryptogenic HCC (15% vs. 4% to 10%, P=0.01). They were more likely to be symptomatic on presentation (44% vs. 32% to 58%, P=0.07), less likely to present within Milan criteria (34% vs. 35% to 63%, P<0.0001), and trended toward decreased 10-year survival rates compared with other ethnic subgroups (9% vs. 25% to 32%, P=0.07). Conclusions: Metabolic risk factors were increasingly prevalent among Asian Americans with HCC. MSEAs, who had the highest incidence of these risk factors, had more advanced tumor stage and trended toward worse survival.
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Chai, Xiaoyu , Storer, Barry E. , Liu, Hien , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Lukez, Alexander , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Krupski, Christa , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Watanaboonyongcharoen, Phandee , Efebera, Yvonne A. , Ferrara, James L.M. , Weisdorf, Daniel J. , Lee, Stephanie J. , Pidala, Joseph, Chen, George L. , Flowers, Mary E.D. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Panoskaltsis‐Mortari, Angela , Weisdorf, Dan , Levine, John E , Holtan, Shernan , Lee, Stephanie J , Wood, William A

Mayo Clinic

Blood | September 14, 2016 | Volume: 128 | Issue: 19 | Pages: 2350-2358

10.1182/blood-2015-09-669846 | PMID 27625357 Get It

Key Points Under current treatment approaches, patients with LA GVHD have poor overall and failure-free survival. Levels of AREG are elevated in LA GVHD, and the AREG/EGF ratio is predictive of overall survival and nonrelapse mortality in LA GVHD.